Helix BioPharma (TSE:HBP) Issues Quarterly Earnings Results

Helix BioPharma (TSE:HBP) released its earnings results on Friday. The biopharmaceutical company reported C($0.01) EPS for the quarter, FiscalAI reports.

Helix BioPharma Stock Performance

TSE HBP remained flat at C$1.58 during trading hours on Friday. The company had a trading volume of 260 shares, compared to its average volume of 2,531. The company has a current ratio of 0.04, a quick ratio of 1.04 and a debt-to-equity ratio of 2.34. Helix BioPharma has a fifty-two week low of C$0.84 and a fifty-two week high of C$5.40. The firm has a fifty day moving average of C$1.74 and a 200-day moving average of C$1.96. The stock has a market cap of C$120.68 million, a price-to-earnings ratio of -26.33 and a beta of 0.42.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.